WuXi Biologics ("WuXi") is a contract development and manufacturing organization, or "CDMO", for biologic drugs. It was founded in 2010 as part of WuXi AppTec and listed on the Hong Kong Stock Exchange in 2017. WuXi provides comprehensive services from conception to commercialization, including drug discovery, clinical and commercial manufacturing, and various support services such as process validation, viral clearance studies, product and cell line characterization, stability studies, and others. It does not conduct clinical trials. WuXi reported CNY 4 billion of revenue in 2019 and a three-year CAGR of 59%. Revenue by geography was 54% from North America, 35% from China, and 8% from Europe. About 45% of its projects are pre-IND (that is prior to clinical testing) and 65% were post-IND.